Prophylaxis for Pneumocystis jirovecii pneumonia in patients treated with TNF-α antagonists might be considered in the presence of 2 or more of the following risk factors: high-dose corticosteroids, concomitant chronic lung disease, persistent lymphopenia, hypoalbuminemia, and hypogammaglobulinemia (LE IIIa; GR D; LA 85%). Here, TNF is linked to Hypoalbuminemia.